- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01657292
Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds
Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oleogel-S10 has shown efficacy and was well tolerated in previous clinical trials in patients with skin lesions. Especially the results in the split-thickness skin graft donor site, which is regarded as an excellent model for any kind of superficial wounds in human skin, suggest that Oleogel-S10 should be efficacious and safe in treatment of grade 2a burns.
The present Phase III clinical trial in grade 2a burns is initiated in order to measure the wound healing progress applying objective methods, i.e., the time to healing and the grade of epithelialization of the wound.
In this study, grade 2a burn wounds are separated into two halves: Following wound cleaning and disinfection, wounds are separated into two wound halves. Randomly assigned, one wound half receives Oleogel-S10 ointment, the other wound half standard of care treatment.
Wound healing progress is documented by photos which are assessed by expert reviewers blinded to the treatment of the wound halves.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany
- Unfallkrankenhaus Berlin
-
Bochum, Germany
- Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil
-
Lübeck, Germany
- Universitätsklinikum Schleswig-Holstein
-
-
-
-
-
Linköping, Sweden
- Linkoping University Hospital
-
Uppsala, Sweden
- University Hospital
-
-
-
-
-
Lausanne, Switzerland
- Centre Hospitalier Universitaire Vaudois
-
-
-
-
-
Birmingham, United Kingdom
- University Hospitals Birmingham NHS Foundation Trust
-
Chelmsford, United Kingdom
- Broomfield Hospital
-
East Grinstead, United Kingdom
- Queen Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients at least 18 years old who have provided written informed consent.
- Presenting with acute grade 2a burn wounds (as graded by an expert surgeon assisted by LDI or a multispectral imaging system) within 48 hours after injury.
- Burn wound caused by fire burn, heat burn or scalding.
- Burn patients with grade 2a burn wounds between 80 cm2 and less than 25% of their TBSA (alternatively, 2 comparable wounds with size more than 40 cm2 each and less than 12.5% of the TBSA each are allowed).
- Patient is able to understand the Informed Consent Form provided and is prepared to comply with all study requirements, including the following: Visiting the trial site for wound dressing changes at least every second day (if patient is not hospitalized) and photo documentation until full wound closure or until the Investigator decides to change medication and/or treatment after day 21 after start of treatment
- Willing to perform all necessary wound dressing changes at the trial site. Also the patient needs to agree to return to site for 3 and 12 months follow-up visits.
- Women of childbearing potential must apply highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly (e.g., implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner))
Exclusion Criteria:
- Suffering from chemical burns, or electrical burns or sunburns
- Having already received treatment for their burn with silver sulfadiazine (obscures photographic wound evaluation).
- Positive blood culture after the burn.
- Diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy.
- A skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
- A history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial.
- Known multiple allergic disorders.
- Taking, or have taken, any investigational drugs within 3 months prior to the screening visit.
- Pregnant or breast feeding women are not allowed to participate in the study.
- Inappropriate to participate in the study, for any reason, in the opinion of the Investigator.
- Mental incapacity or language barriers precluding adequate understanding or co-operation or willingness to follow study procedures.
- Previous participation in this study.
- Employee at the investigational site, relative or spouse of the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oleogel-S10 ointment
Intra-individual comparison.
Oleogel-S10 ointment is administered to one randomly assigned wound half.
|
Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Other Names:
|
OTHER: Octenilin® wound gel
Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
|
Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care
Time Frame: 2 to 3 weeks
|
Photo-based evaluation by independent experts blinded to the treatment regime.
|
2 to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intra-individual Difference in Time to Wound Closure Between Wound Halves, Either Treated With Oleogel-S10 or Treated With Standard of Care
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Time From Study Start After Burn Accident Until Wound Closure is Achieved Separately for Wound Halves Treated With Oleogel-S10 vs. Standard of Care
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Percentage of Patients With Wound Closure at Different Time Points
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Percentage of Wound Epithelialization at Different Time Points as Assessed by the Investigator
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Likert Scale Rating of Efficacy (Evaluated by Both the Investigators and Patients)
Time Frame: 2 to 3 weeks
|
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to grade the efficacy of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
|
2 to 3 weeks
|
Cosmetic Outcome After 3 and 12 Months After Burn Accident, in Relation to Texture, Redness, Growth of Hair and Pigmentation, Based on Blinded Photo Evaluation
Time Frame: 3 and 12 months
|
3 and 12 months
|
|
Likert Scale Rating of Tolerance (Evaluated by Both the Investigators and Patients)
Time Frame: 2 to 3 weeks
|
By direct comparison of the separate simultaneous treatments for the two wound halves, patients and investigators, respectively, are asked to provide their opinion on the tolerance of Oleogel-S10 Versus Standard of Care on a questionnaire with a 5-point graded visual analogue scale
|
2 to 3 weeks
|
PK Data: Systemic Presence/Concentration of Betulin in Blood Plasma Samples
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Microbial Colonization of the Wound Halves
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
|
Assessment of Adverse Events
Time Frame: 2 to 3 weeks
|
2 to 3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernd Hartmann, Dr., Trauma Hospital Berlin, Warener Str. 7, 12683 Berlin, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBW-11
- 2012-000362-38 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burns
-
American Scitech InternationalJohnson & JohnsonUnknownBurns | Electric BurnsUnited States
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
RenovaCare, IncActive, not recruitingBurns | Burns Second Degree | Burns Deep Second DegreeUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
Sun Yat-sen UniversityCompleted
-
MediWound LtdActive, not recruitingThermal BurnsUnited States, United Kingdom, Spain, Georgia, Belgium, Poland, Germany, Hungary, India, Italy, Netherlands, Romania, Slovakia, Ukraine
-
Virginia Commonwealth UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityCompleted
-
St. Justine's HospitalRecruiting
Clinical Trials on Oleogel-S10 ointment
-
Amryt Research LimitedCompletedEpidermolysis BullosaUnited States, Spain, Israel, Australia, France, Denmark, Switzerland, Italy, Hong Kong, Argentina, Austria, Brazil, Chile, Colombia, Czechia, Georgia, Germany, Greece, Hungary, Ireland, Romania, Russian Federation, Serbia, Singapore, U... and more
-
Birken AGCompletedWoundsGermany, Austria, Bulgaria, Czechia, Finland, Poland
-
Birken AGCompletedInherited Epidermolysis BullosaGermany
-
Birken AGCompletedWoundsSpain, France, Greece, Latvia
-
Birken AGCompletedAccelerating the Epithelialization of Split Thickness Skin GraftGermany
-
Birken AGUniversity Hospital TuebingenCompletedActinic KeratosesGermany, Greece
-
Clinical Nutrition Research Centre, SingaporeCompletedDiabetes Mellitus, Type 2 | Cardiovascular Risk FactorSingapore
-
University Hospital, GhentCompletedVenous Insufficiency of Leg | Nocturia | Edema Leg | Bio-Impedance MeasurementsBelgium
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer StageUnited States
-
The Catholic University of KoreaCompletedGrowth | Child Development | Disability, DevelopmentalKorea, Republic of